Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Advancements in Heart Failure Management: From Precision Medicine to Therapeutic...
share announcement

Advancements in Heart Failure Management: From Precision Medicine to Therapeutic Innovations

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 25 August 2024 | Viewed by 307

Special Issue Editor

Dr. Akito Nakagawa

E-Mail Website
Guest Editor
1. Nakagawa Clinic, Shoushoukai Healthcare Corporation, Suita, Osaka 564-0082, Japan
2. Department of Cardiovascular Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan
3. Department of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan
Interests: heart failure; imaging; echocardiography; observational studies; medical informatics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pharmacological innovations as well as multifactorial approaches are helping to expand the potential of managing the heterogeneous nature of heart failure. Promising gene-editing technologies offer potential routes to correct genetic mutations that cause heart failure. Regenerative medicine approaches, including stem cell therapy and tissue engineering, hold great potential for repairing damaged cardiac tissue and restoring function. Precision medicine approaches that take into account genetics, biomarkers, and comorbidities to tailor heart failure treatment to individual patient profiles are gaining attention. The integration of artificial intelligence and machine learning into heart failure management has also enabled the development of predictive models for early intervention, risk stratification, and personalized treatment recommendations.

Despite the availability of current therapies, it should be recognized that not all patients will have an ideal response and often show persistent progression. The prevalence of heart failure continues to increase, and the limitations of existing therapies make the development of new treatment strategies an urgent necessity.

We welcome submissions of original research as well as systematic reviews on the topic of advancements in heart failure management and treatment. State-of-the-art narrative reviews are also eligible for publication.

Dr. Akito Nakagawa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • developments in diagnostics
  • pharmacological innovations
  • device-based interventions
  • multi-omics approaches
  • lifestyle modifications

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1417 KiB  
Article
Clinical Implications of Remote Dielectric Sensing-Guided Management
by Yu Nomoto, Teruhiko Imamura, Toshihide Izumida, Nikhil Narang and Koichiro Kinugawa
J. Clin. Med. 2024, 13(10), 2906; https://doi.org/10.3390/jcm13102906 - 14 May 2024
Abstract
Background: Remote dielectric sensing (ReDS) systems can quantify the degree of pulmonary congestion rapidly and non-invasively. However, the clinical implications of ReDS-guided medication adjustment remain uncertain. Methods: Patients hospitalized to treat cardiovascular diseases, including heart failure, valvular disease, and coronary artery disease, and [...] Read more.
Background: Remote dielectric sensing (ReDS) systems can quantify the degree of pulmonary congestion rapidly and non-invasively. However, the clinical implications of ReDS-guided medication adjustment remain uncertain. Methods: Patients hospitalized to treat cardiovascular diseases, including heart failure, valvular disease, and coronary artery disease, and underwent ReDS measurement before index discharge between 2021 and 2022 were included. According to our institutional protocol, ReDS values were blinded to the attending clinicians until February 2022 (blind period). After the period, ReDS values were timely opened to the attending clinicians, and medications such as diuretics were adjusted according to the ReDS values (target value between 20% and 35%) before index discharge (open period). A composite primary outcome of all-cause death and heart failure readmissions was compared between the two groups. Results: A total of 183 patients were included (median 79 years old, 101 men), consisting of 138 patients in the blind period and 45 patients in the open period. During a median of 646 (401, 818) days after the index discharge, 33 patients experienced the primary outcome of interest. Management during the open period, where medications were adjusted according to ReDS values, was independently associated with a lower incidence of the primary outcome with an adjusted hazard ratio of 0.22 (95% confidence interval 0.05–0.94, p = 0.041), as compared with those of the blind period. Conclusions: According to the findings of the present retrospective study, ReDS-guided management may have the potential to reduce the risk of mortality and heart failure admission in individuals hospitalized for cardiovascular diagnoses. Further prospective randomized control trials involving those with a variety of background etiologies and clinical scenarios are warranted to validate our findings and establish optimal ReDS-guided management. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Management: From Precision Medicine to Therapeutic Innovations)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop